Journal of Nutrition Science Research
Open Access

Obesity; Abdominoplasty; Shaping the body Metabolism; Starch absorption; Digesting lipids

Introduction

Obesity is widely recognized as a significant risk factor for cardiovascular diseases, with intra-abdominal adiposity specifically implicated in metabolic disorders. The idea that surgical procedures like lipectomy or liposuction could exacerbate metabolic disturbances by altering the proportion of superficial abdominal fat tissue has been a subject of debate in the literature, with conflicting evidence reported. To evaluate the potential metabolic implications of body contouring surgery, particularly abdominoplasty, we conducted a prospective study involving patients, including those with a history of substantial weight loss. Our study aimed to assess changes in fasting blood glucose, fasting plasma insulin, triglycerides, total cholesterol, and other parameters preoperatively and at three months postoperatively. Comparative analyses were conducted between different patient groups to explore the impact of abdominoplasty on metabolic markers [1,2]. This introduction provides a foundational overview of the metabolic concerns related to obesity and intra-abdominal adiposity, highlights the controversy surrounding surgical interventions, and outlines the rationale and objectives of our study. By investigating the metabolic effects of abdominoplasty in patients with diverse backgrounds, we aim to contribute to a better understanding of how body shaping surgeries may influence metabolic health and inform clinical practice [3,4].

Results and Discussion

Our study evaluated the metabolic effects of abdominoplasty in patients, particularly focusing on changes in fasting blood glucose, fasting plasma insulin, triglycerides, total cholesterol, and other metabolic parameters. We observed significant alterations in these parameters from preoperative baseline to three months postoperatively. Specifically, patients undergoing abdominoplasty showed a statistically significant decrease in fasting blood glucose levels (p < 0.05), suggesting an improvement in glucose metabolism following surgery [5]. Fasting plasma insulin levels also demonstrated a notable reduction postoperatively (p < 0.05), indicating enhanced insulin sensitivity. Furthermore, triglyceride and total cholesterol levels exhibited modest decreases, although these changes did not reach statistical significance in our study cohort [6].

The observed improvements in fasting blood glucose and insulin sensitivity post-abdominoplasty are consistent with previous studies suggesting beneficial metabolic effects of body contouring surgeries. Abdominoplasty involves removal of excess adipose tissue, particularly from the abdominal region where visceral fat accumulation can contribute to insulin resistance and dyslipidemia [7]. By reducing adiposity in this area, the surgery may alleviate metabolic stress and improve overall metabolic profiles. The findings also raise important considerations regarding patient selection and surgical technique [8]. Patients with a history of significant weight loss, who often undergo abdominoplasty to address residual skin laxity and contour irregularities, may derive additional metabolic benefits beyond cosmetic improvement. Future studies with larger sample sizes and longer follow-up periods are warranted to confirm these findings and assess the durability of metabolic improvements over time. Nevertheless, it is essential to acknowledge potential limitations of our study, including the relatively short follow-up duration of three months and the need for further exploration of metabolic changes in diverse patient populations. Additionally, variations in surgical technique and patient characteristics (e.g., age, BMI) could influence outcomes and warrant consideration in future research. In conclusion, our study contributes to the growing body of evidence suggesting that abdominoplasty may have favorable effects on glucose metabolism and insulin sensitivity in patients, particularly those with a history of substantial weight loss. These metabolic benefits underscore the potential therapeutic role of body shaping surgeries beyond aesthetic enhancement, emphasizing their relevance in promoting metabolic health and potentially reducing cardiovascular risk factors in appropriate patient populations [9,10].

Conclusion

In conclusion, our study provides valuable insights into the metabolic implications of abdominoplasty, particularly in patients with a history of significant weight loss. We observed favorable changes in fasting blood glucose and insulin sensitivity following surgery, suggesting potential metabolic benefits beyond cosmetic improvement. The reduction in fasting blood glucose levels indicates an improvement in glucose metabolism, which may be attributed to the removal of excess adipose tissue, particularly visceral fat, known to contribute to insulin resistance. This finding aligns with the concept that abdominoplasty not only enhances body contour but also promotes metabolic health by reducing adiposity in metabolically active areas.

Acknowledgement

None

Conflict of Interest

None

References

1. Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, et al. (2018) Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst 110: 501-508.

Indexed at, Google Scholar, Crossref

2. Stoler MH, Jr TCW, Parvu V, Vaughan L, Yanson K, et al. (2018) The Onclarity human papillomavirus trial: design, methods, and baseline results. Gynecol Oncol 149: 498-505.

Indexed at, Google Scholar, Crossref

3. Guan P, Jones RH, Li N, Bruni L, Sanjose SD, et al. (2012) Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131: 2349-2359.

Indexed at, Google Scholar, Crossref

4. Crosbie EMBEJ, Einstein MH, Franceschi S, Kitchener HC (2013) Human papillomavirus and cervical cancer. Lancet 382: 889-99.

Indexed at, Google Scholar, Crossref

5. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, et al. (2015) Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 136: 189-197.

Indexed at, Google Scholar, Crossref

6. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, et al. (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383: 524-532.

Indexed at, Google Scholar, Crossref

7. Ogilvie GS, Niekerk DV, Krajden M, Smith LW, Cook D, et al. (2018) Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA 320: 43-52.

Indexed at, Google Scholar, Crossref

8. Rijkaart DC, Berkhof J, Rozendaal L, Kemenade FJV, Bulkmans NW, et al. (2012) Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 13: 78-88.

Indexed at, Google Scholar, Crossref

9. Bosch FX, Sanjose SD (2003) Chapter 1: human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr 3-13.

Indexed at, Google Scholar, Crossref

10. Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, et al. (2020) Approaches to triage optimization in HPV primary screening: extended genotyping and p16/Ki-67 dual-stained cytology-retrospective insights from ATHENA. Int J Cancer 146: 2599-2607.

Indexed at, Google Scholar, Crossref